Stock Spotlight: Nanosonics Ltd (ASX:NAN)

About Nanosonics

Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.



Key Stats

Source: Yahoo Finance. Data as of 05/08/25.

Price Performance

Growth Potential

  • Requirement for ultrasound disinfection. Ultrasound transducers must be disinfected between patients to prevent cross-infection. Trophon EPR is a significant improvement above traditional methods (soak, spray, wipe or other manual reprocessing/disinfection method). For instance, traditional soaking takes ~25 minutes versus Trophon which takes ~7-8 minutes to disinfect ultrasound probes.
  • Potential addressable installed base of ~120,000 Trophon EPR units globally (~40,000 in the US, Europe and Rest of World each).
  • New guidelines and regulation drive pathways to reinforce requirements for high level disinfection. For instance, new guidelines in Australia and New Zealand setting Trophon as the standard in high level disinfection.
  • Continued growth in North America to be driven by its direct sales team with adoption remaining strong and Trophon becoming the standard of care.
  • CORIS launch in FY26 could potentially exceed market expectations
  • Large and credible distribution partner is retained in GE Healthcare with demand for safety inventory.
  • Managed Equipment Service business model (MES) in the UK overcoming capital budget constraints by clients.
  •  Progress with geographic expansion.
  • Strong balance sheet to support growth strategy

Key Risks

  • Competitive pressures as potential entrants enter the market.
  • Non-receptive markets where NAN’s product is considered overkill compared to traditional disinfection methods such as using sterilized wipes.
  • CORIS launch in FY26 disappoints relative to expectations.
  • Key customer risk as one customer is NAN’s largest customer.
  • Product faults or incidents where recalls are required.
  • Adverse foreign currency movements in AUD/USD.
  • Poor execution of R&D with no progress.
  • Nature of business makes it prone to easily reaching a natural penetration rate, where growth becomes subdued.

Subscribe to our newsletter

Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.

Speak to an Advisor

November 4, 2026
The RBA lifted the cash rate to 4.85% in a split vote. Here’s how higher rates flow through ASX sectors, company earnings, dividends and valuations.
October 29, 2026
Inside Anthropic’s IPO filing: explore its soaring revenue, computing commitments, reported losses and governance structure, and what the disclosures mean for investors.
October 21, 2026
Big Tech reports next week. Learn how to read earnings releases and filings, and what to look for in AI spending, cloud growth, cash flow and guidance.
October 14, 2026
Understand how AI investment could affect global financial stability, as the IMF and RBA warn of rising debt, market concentration and funding risks.
October 8, 2026
Firmus’ proposed mega-IPO puts a spotlight on the cost, capital intensity and risks of building AI infrastructure as investors weigh the next phase of the AI boom.
October 6, 2026
About Electro Optic Systems Holdings Ltd. Electro Optic Systems Holdings Limited engages in the development, manufacture, and sale of telescopes and dome enclosures, laser satellite tracking systems, remote weapon systems, and high laser weapon. It operates through Defense Systems and Space Systems segments. The company develops, manufactures, and markets fire control, surveillance, weapon systems, and high energy laser to military customers. It also provides passive optical and laser sensing equipment; optical, microwave and on-the-move radio and satellite products; and laser-based surveillance systems with space tracking capability. In addition, the company offers counter-drone, firepower, force protection, and UGV and marine lethality systems, as well as high energy laser weapon; optical tracking systems, space control, space domain awareness, satellite laser ranging, space sustainability, and precision optics. It operates in Australia, the United States, Singapore, the United Arab Emirates, the United Kingdom, New Zealand, the Netherlands, North America, Germany, and rest of Europe. Electro Optic Systems Holdings Limited was founded in 1983 and is based in Symonston, Australia. Source: EODHD Key Stats
October 6, 2026
About Liontown Ltd. Liontown Limited engages in the exploration, evaluation, and development of mineral properties in Australia. It primarily explores for lithium, gold, and nickel deposits. The company's flagship property is the Kathleen Valley lithium project located in Perth, Western Australia. The company was formerly known as Liontown Resources Limited and change its name to Liontown Limited in November 2025. Liontown Limited was incorporated in 2006 and is headquartered in West Perth, Australia. Source: EODHD Key Stats
September 30, 2026
The RBA has raised rates to 4.60% as inflation pressures persist. Explore the impact of energy costs, AI demand and the key signals investors should watch next.
September 22, 2026
Discover how advances in genomics, AI, diagnostics and gene editing are creating a broader healthcare opportunity and where commercial value is emerging.
September 15, 2026
The AI trade is being forced to rethink the pace of progress. Here is what investors should watch across Nvidia, chips, AI spending, software and adoption.